Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800

Recent News


CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update


CymaBay Therapeutics Announces Multiple Presentations at DDW 2019


CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8

Upcoming Event

May 18 2019

Digestive Disease Week® (DDW)

May 18 - May 21, 2019

San Diego, California

Q1 2019 Quarterly Results